Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) has earned a consensus recommendation of "Hold" from the five ratings firms that are currently covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $366.67.
A number of equities research analysts have recently weighed in on BIO shares. Weiss Ratings upgraded shares of Bio-Rad Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a report on Monday, November 9th. Zacks Research raised shares of Bio-Rad Laboratories from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 11th. Royal Bank Of Canada increased their price target on Bio-Rad Laboratories from $390.00 to $440.00 and gave the company an "outperform" rating in a report on Thursday, November 5th. Citigroup raised their target price on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the stock a "hold" rating in a research report on Wednesday, August 5th. Finally, Wells Fargo & Company upped their price target on Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 5th.
Get Our Latest Stock Report on BIO
Insider Activity
In other news, EVP Courtney C. Enloe sold 902 shares of the stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $386.17, for a total value of $348,325.34. Following the sale, the executive vice president directly owned 750 shares in the company, valued at approximately $289,627.50. This trade represents a 54.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jonathan P. Divincenzo sold 919 shares of the business's stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $390.47, for a total transaction of $358,841.93. Following the sale, the chief operating officer owned 1,962 shares of the company's stock, valued at $766,102.14. This represents a 31.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,221 shares of company stock worth $1,247,049 over the last 90 days. 30.34% of the stock is currently owned by company insiders.
Institutional Trading of Bio-Rad Laboratories
Several institutional investors and hedge funds have recently modified their holdings of BIO. American Century Companies Inc. lifted its holdings in Bio-Rad Laboratories by 16.3% in the third quarter. American Century Companies Inc. now owns 7,946 shares of the medical research company's stock worth $3,001,000 after purchasing an additional 1,114 shares during the period. Kestra Advisory Services LLC grew its stake in Bio-Rad Laboratories by 11.0% in the third quarter. Kestra Advisory Services LLC now owns 911 shares of the medical research company's stock valued at $344,000 after purchasing an additional 90 shares in the last quarter. Integrated Wealth Concepts LLC increased its stake in shares of Bio-Rad Laboratories by 11,148.9% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 10,349 shares of the medical research company's stock worth $3,909,000 after purchasing an additional 10,257 shares during the last quarter. Algert Global LLC lifted its position in shares of Bio-Rad Laboratories by 1,094.2% in the third quarter. Algert Global LLC now owns 20,540 shares of the medical research company's stock worth $7,758,000 after buying an additional 18,820 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Bio-Rad Laboratories during the 3rd quarter worth about $386,000. Hedge funds and other institutional investors own 65.24% of the company's stock.
Bio-Rad Laboratories Stock Down 2.5%
Shares of NYSE:BIO opened at $358.17 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.18 and a quick ratio of 2.37. Bio-Rad Laboratories has a 1 year low of $236.73 and a 1 year high of $396.23. The business's 50-day moving average is $371.65 and its 200-day moving average is $319.11. The company has a market capitalization of $9.63 billion, a price-to-earnings ratio of 9.43 and a beta of 1.06.
Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The medical research company reported $2.65 earnings per share for the quarter, beating analysts' consensus estimates of $2.23 by $0.42. The company had revenue of $656.40 million for the quarter, compared to analyst estimates of $649.94 million. Bio-Rad Laboratories had a net margin of 39.45% and a return on equity of 3.58%. The firm's revenue was up .5% on a year-over-year basis. During the same period last year, the firm earned $2.26 earnings per share. Equities research analysts predict that Bio-Rad Laboratories will post 9.71 earnings per share for the current year.
Bio-Rad Laboratories Company Profile
(
Get Free Report)
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.